Amgen: all 1,085 studies

Page 7 of 11. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.

• Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityCompletedNCT07229157Phase 1
• Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsCompletedNCT07226778Phase 1
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyActive, not recruitingNCT07226765Phase 3
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyActive, not recruitingNCT07225686Phase 3
• A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusActive, not recruitingNCT07160257Phase 1
• Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer PatientsCompletedNCT07143513
• A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese ParticipantsCompletedNCT07142642Phase 1
• A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT07134088Phase 1/2
• Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease PatientsCompletedNCT07085117
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Phase 3
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseActive, not recruitingNCT06987695Phase 3
• A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityCompletedNCT06976372Phase 1
• Single and Multiple Ascending Dose Study of AMG 378 in Healthy ParticipantsTerminatedNCT06910709Phase 1
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)Active, not recruitingNCT06898957Phase 1
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingNCT06858878Phase 3
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingNCT06858839Phase 3
• A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight LossCompletedNCT06761703
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCActive, not recruitingNCT06745323Phase 2
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Active, not recruitingNCT06700343Phase 3
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingNCT06691984Phase 3
• A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese ParticipantsCompletedNCT06674941Phase 1
• A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingNCT06660173Phase 2
• A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaActive, not recruitingNCT06637371Phase 1
• A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruitingNCT06593522Phase 2
• AMG 335 Expanded Access Program for IgG4-Related DiseaseApproved for marketingNCT06590051
• A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland ChinaActive, not recruitingNCT06588153Phase 4
• Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityCompletedNCT06585462Phase 1
• A Study of TEPEZZA Subcutaneous Administration in Healthy AdultsCompletedNCT06563856Phase 1
• Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerActive, not recruitingNCT06555796Phase 1
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisTerminatedNCT06527404Phase 3
• A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsCompletedNCT06438263Phase 1
• Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Active, not recruitingNCT06430866Phase 3
• A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy ParticipantsCompletedNCT06411860Phase 1
• A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseActive, not recruitingNCT06401044Phase 1/2
• A Study of TEPEZZA® Treatment in Participants With Thyroid Eye DiseaseCompletedNCT06389578Phase 1
• A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaTerminatedNCT06376045Phase 2
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingNCT06360354Phase 1
• A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightCompletedNCT06352892Phase 1
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingNCT06333951Phase 1
• Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaActive, not recruitingNCT06332014Phase 4
• Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.Active, not recruitingNCT06321601Phase 3
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's SyndromeTerminatedNCT06312020Phase 2
• A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerActive, not recruitingNCT06311721Phase 3
• A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular DiseaseActive, not recruitingNCT06295679
• A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseaseActive, not recruitingNCT06248619Phase 3
• A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateActive, not recruitingNCT06245408Phase 3
• A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisCompletedNCT06224192Phase 3
• A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsCompletedNCT06214481Phase 1
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Phase 3
• Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of SimvastatinCompletedNCT06207682Phase 1
• Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)Active, not recruitingNCT06180278Phase 4
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)CompletedNCT06122649Phase 3
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)Active, not recruitingNCT06117774Phase 3
• A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityCompletedNCT06104124Phase 3
• A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisCompletedNCT06088199Phase 3
• Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerApproved for marketingNCT06064500
• A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy ParticipantsWithdrawnNCT06061523Phase 1
• A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3
• Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)Active, not recruitingNCT06054113Phase 2
• A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy ParticipantsCompletedNCT06004960Phase 1
• A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsCompletedNCT06004947Phase 1
• A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT06004934Phase 1
• Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese ParticipantsCompletedNCT05995691Phase 1
• A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy ParticipantsCompletedNCT05988034Phase 1
• A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168CompletedNCT05988021Phase 1
• A Study of CCX168 in Japanese and Caucasian Healthy Adult MalesCompletedNCT05988008Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsCompletedNCT05984251Phase 1
• A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsCompletedNCT05975073Phase 1/2
• Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Phase 3
• A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal CancerCompletedNCT05913115Phase 1
• A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult ParticipantsCompletedNCT05909852Phase 1
• A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3
• Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisCompletedNCT05891119Early Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese ParticipantsCompletedNCT05885451Phase 1
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)TerminatedNCT05882877Phase 3
• A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy ParticipantsCompletedNCT05873907Phase 1
• Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid TumorsTerminatedNCT05800964Phase 1
• Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative ColitisTerminatedNCT05672199Phase 2
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusCompletedNCT05669599Phase 2
• A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05599828Phase 1
• Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy ParticipantsCompletedNCT05598281Phase 1
• Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus ErythematosusTerminatedNCT05591222Phase 2
• Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05581992Phase 1
• A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05581758Phase 1
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialActive, not recruitingNCT05581303Phase 3
• A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male SubjectsCompletedNCT05578859Phase 1
• A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy ParticipantsCompletedNCT05577624Phase 1
• A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy ParticipantsCompletedNCT05571163Phase 1
• A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy ParticipantsCompletedNCT05568082Phase 1
• Study to Evaluate HZN-457 in Healthy VolunteersCompletedNCT05565768Phase 1
• A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05565560Phase 3
• Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy ParticipantsCompletedNCT05550129Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal ImpairmentCompletedNCT05489614Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic ImpairmentCompletedNCT05481411Phase 1
• Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With ObesityCompletedNCT05406115Phase 1
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)CompletedNCT05378529Not applicable
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT05361395Phase 1
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedNCT05325866Phase 1/2
• Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive TherapyWithdrawnNCT05323617Phase 2

← Amgen overview and focus areas